AR062469A1 - Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos. - Google Patents
Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos.Info
- Publication number
- AR062469A1 AR062469A1 ARP070103713A ARP070103713A AR062469A1 AR 062469 A1 AR062469 A1 AR 062469A1 AR P070103713 A ARP070103713 A AR P070103713A AR P070103713 A ARP070103713 A AR P070103713A AR 062469 A1 AR062469 A1 AR 062469A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr19r20
- cr14r15
- nhc
- noc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 119
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 abstract 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000002547 anomalous effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83916306P | 2006-08-21 | 2006-08-21 | |
| US87160006P | 2006-12-22 | 2006-12-22 | |
| US91762407P | 2007-05-11 | 2007-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062469A1 true AR062469A1 (es) | 2008-11-12 |
Family
ID=38800915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103713A AR062469A1 (es) | 2006-08-21 | 2007-08-21 | Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7893085B2 (esLanguage) |
| EP (1) | EP2069359B1 (esLanguage) |
| JP (1) | JP5349306B2 (esLanguage) |
| KR (1) | KR101475088B1 (esLanguage) |
| AR (1) | AR062469A1 (esLanguage) |
| AU (1) | AU2007286807B2 (esLanguage) |
| BR (1) | BRPI0714629A2 (esLanguage) |
| CA (1) | CA2660963A1 (esLanguage) |
| CL (1) | CL2007002431A1 (esLanguage) |
| ES (1) | ES2528797T3 (esLanguage) |
| IL (1) | IL197060A (esLanguage) |
| MX (1) | MX2009001875A (esLanguage) |
| NO (1) | NO20091198L (esLanguage) |
| PE (2) | PE20120049A1 (esLanguage) |
| TW (1) | TWI426078B (esLanguage) |
| WO (1) | WO2008024724A1 (esLanguage) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE531720T1 (de) * | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| US8637246B2 (en) | 2010-02-25 | 2014-01-28 | Dana-Farber Cancer Institute, Inc. | BRAF mutations conferring resistance to BRAF inhibitors |
| BR112012022801B8 (pt) | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| CN109311868B (zh) | 2015-12-22 | 2022-04-01 | 尚医治疗有限责任公司 | 用于治疗癌症和炎性疾病的化合物 |
| CA3018406A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| DK3624795T3 (da) * | 2017-05-19 | 2022-05-23 | Nflection Therapeutics Inc | Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser |
| PL3624796T3 (pl) | 2017-05-19 | 2025-06-30 | Nflection Therapeutics, Inc. | Związki pirolopirydyno-anilinowe do leczenia zaburzeń skórnych |
| EP3642209B1 (en) | 2017-06-21 | 2023-11-29 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| MX2020002553A (es) | 2017-09-08 | 2020-07-22 | Hoffmann La Roche | Metodos de diagnostico y terapeuticos para el cancer. |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| KR20250044476A (ko) | 2018-07-09 | 2025-03-31 | 베링거잉겔하임베트메디카게엠베하 | 구충성 헤테로시클릭 화합물 |
| WO2020106308A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| CN117551073A (zh) | 2018-11-20 | 2024-02-13 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病噻吩基苯胺化合物 |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| KR20220002890A (ko) | 2019-03-19 | 2022-01-07 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물 |
| KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN118339164A (zh) | 2021-11-01 | 2024-07-12 | 勃林格殷格翰动物保健有限公司 | 驱虫吡咯并哒嗪化合物 |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328920A (en) | 1991-04-17 | 1994-07-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted (pyridinylamino)-indoles |
| JPH06509087A (ja) | 1991-07-05 | 1994-10-13 | メルク シヤープ エンド ドーム リミテツド | 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用 |
| US5214204A (en) | 1991-07-19 | 1993-05-25 | Abbott Laboratories | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity |
| ATE147386T1 (de) | 1991-08-12 | 1997-01-15 | Takeda Chemical Industries Ltd | Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel |
| CA2083891A1 (en) | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
| JPH05345780A (ja) | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| US5350748A (en) | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
| DE4425609A1 (de) | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| EP0922043B1 (en) | 1997-04-24 | 2002-01-30 | Dow AgroSciences LLC | Pesticidal 3-(substituted phenyl)-5-(thienyl or furyl)-1,2,4-triazoles |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| FR2777886B1 (fr) | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2181366T3 (es) | 1998-06-30 | 2003-02-16 | Lilly Co Eli | Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina. |
| CA2335310A1 (en) | 1998-06-30 | 2000-01-06 | Kenneth Lee Hauser | Azepine derivatives having effects on serotonin related systems |
| US6353008B1 (en) | 1998-06-30 | 2002-03-05 | Eli Lilly And Company | Pyrrolidine and pyrroline derivatives having effects on serotonin related systems |
| US6410562B1 (en) | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| HRP20010524A2 (en) | 1999-01-13 | 2002-08-31 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| FR2799756B1 (fr) | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AR027133A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| KR100773621B1 (ko) * | 2000-07-19 | 2007-11-05 | 워너-램버트 캄파니 엘엘씨 | 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르 |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| WO2003070731A2 (en) | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| CA2478374C (en) * | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CN1652792A (zh) | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
| US20040009976A1 (en) | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| AU2003257145B2 (en) | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| JP2005104838A (ja) | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| GB0316232D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| WO2005013996A2 (en) | 2003-08-07 | 2005-02-17 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| DE10351436A1 (de) | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| ES2299906T3 (es) | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | Moduladores de receptores activados por proliferadores de peroxisomas. |
| EA010298B1 (ru) | 2003-12-19 | 2008-08-29 | Биовитрум Аб (Пабл) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором |
| CA2545821C (en) | 2003-12-22 | 2010-09-21 | Basilea Pharmaceutica Ag | Aroylfuranes and aroylthiophenes |
| MXPA06007213A (es) | 2003-12-23 | 2006-08-18 | Pfizer Prod Inc | Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos. |
| AU2006232620A1 (en) * | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors |
| KR20080052630A (ko) | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Ｒａｆ 억제제 화합물 및 그의 사용 방법 |
| ATE531720T1 (de) | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
| CA2662285A1 (en) | 2006-08-31 | 2008-03-06 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
-
2007
- 2007-08-20 EP EP07814268.4A patent/EP2069359B1/en active Active
- 2007-08-20 US US11/894,345 patent/US7893085B2/en not_active Expired - Fee Related
- 2007-08-20 ES ES07814268.4T patent/ES2528797T3/es active Active
- 2007-08-20 CA CA002660963A patent/CA2660963A1/en not_active Abandoned
- 2007-08-20 WO PCT/US2007/076340 patent/WO2008024724A1/en not_active Ceased
- 2007-08-20 MX MX2009001875A patent/MX2009001875A/es active IP Right Grant
- 2007-08-20 KR KR1020097005785A patent/KR101475088B1/ko not_active Expired - Fee Related
- 2007-08-20 BR BRPI0714629-9A patent/BRPI0714629A2/pt not_active IP Right Cessation
- 2007-08-20 JP JP2009525719A patent/JP5349306B2/ja not_active Expired - Fee Related
- 2007-08-20 AU AU2007286807A patent/AU2007286807B2/en not_active Ceased
- 2007-08-21 AR ARP070103713A patent/AR062469A1/es unknown
- 2007-08-21 PE PE2011001541A patent/PE20120049A1/es not_active Application Discontinuation
- 2007-08-21 TW TW096130981A patent/TWI426078B/zh not_active IP Right Cessation
- 2007-08-21 PE PE2007001134A patent/PE20081359A1/es not_active Application Discontinuation
- 2007-08-21 CL CL200702431A patent/CL2007002431A1/es unknown
-
2009
- 2009-02-16 IL IL197060A patent/IL197060A/en not_active IP Right Cessation
- 2009-03-20 NO NO20091198A patent/NO20091198L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2528797T3 (es) | 2015-02-12 |
| WO2008024724A1 (en) | 2008-02-28 |
| JP5349306B2 (ja) | 2013-11-20 |
| PE20120049A1 (es) | 2012-02-16 |
| KR20090047538A (ko) | 2009-05-12 |
| EP2069359B1 (en) | 2014-11-12 |
| IL197060A0 (en) | 2009-11-18 |
| NO20091198L (no) | 2009-05-20 |
| US7893085B2 (en) | 2011-02-22 |
| EP2069359A1 (en) | 2009-06-17 |
| TWI426078B (zh) | 2014-02-11 |
| AU2007286807B2 (en) | 2013-03-21 |
| AU2007286807A1 (en) | 2008-02-28 |
| TW200823222A (en) | 2008-06-01 |
| PE20081359A1 (es) | 2008-11-27 |
| US20080081821A1 (en) | 2008-04-03 |
| IL197060A (en) | 2014-12-31 |
| BRPI0714629A2 (pt) | 2013-05-07 |
| JP2010501584A (ja) | 2010-01-21 |
| MX2009001875A (es) | 2009-03-02 |
| CL2007002431A1 (es) | 2008-03-14 |
| KR101475088B1 (ko) | 2014-12-23 |
| CA2660963A1 (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062469A1 (es) | Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos. | |
| AR062468A1 (es) | Compuestos de azabenzofuranil y metodos de uso | |
| AR064031A1 (es) | Compuestos de azaindolilo y metodos de uso | |
| AR069803A1 (es) | 5- anilinoimiazopiridinas y metodos de uso | |
| AR072092A1 (es) | Diazacarbazoles y metodos de uso | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
| RU2011103434A (ru) | Изоиндолоны и способы их применения | |
| AR048346A1 (es) | Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central. | |
| AR069637A1 (es) | Derivados de pirazinas | |
| CO6220878A2 (es) | Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo | |
| AR075022A1 (es) | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
| AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
| AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
| AR073106A2 (es) | Inhibidores de polimerasa virica | |
| AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
| BR112018016671A2 (pt) | sulfonilureias e compostos relacionados e uso do mesmo | |
| AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
| AR049104A1 (es) | Pirimidinas como inhibidores de plk, composiciones farmaceuticas que las contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades proliferativas, inflamatorias y autoinmunes. | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| CO6150160A2 (es) | Derivados de morfolino pirimidina utiles en el tratamiento de desordenes proliferativos | |
| AR059246A1 (es) | Compuestos heterobiciclicos de tiofeno y metodos de uso | |
| AR058542A1 (es) | Compuestos herbicidas derivados de isoxazolina, procesos de preparacon, composiciones que los comprenden y uso en el control o inhibicion de plantas. | |
| AR050793A1 (es) | Derivados de isoxazolina, procedimientos para su preparacion y su uso como herbicidas | |
| AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |